Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer

Tracess B. Smalley & Jennifer M. Binning · 2025-08-26

Human papillomavirus (HPV) remains a global health burden, yet there are no targeted therapies for HPV-related cancers. The HPV E6 protein is essential for tumorigenesis and immune evasion, making it an attractive target for antiviral drug development. In this study, we developed an E6-targeting proteolysis targeting chimera (PROTAC) that inhibits the growth of HPV
Links
DOIPubMed
Journal
Molecular Therapy
Institutions
Unknown Institution
Authors
Tracess B. Smalley, Jennifer M. Binning
Funding
Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapyDevelopmental FundsDual E3 ligase function of TRIM25 in modulating innate immunityNCI NIH HHS Grant L70 CA284384Biophysical basis for enzyme mediated deglycation in protein repairNIH National Institute of General Medical Sciences Grant K99/R00 GM154063Biophysical basis for enzyme mediated deglycation in protein repairH. Lee Moffitt Cancer Center and Research Institute FundingLeadership, Planning and EvaluationPredict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapyAmerican Cancer Society Inc Grant PF-22-041-01-ETCentre for Incubation, Innovation, Research and Consultancy FundingNational Institutes of Health Funding

NCI NIH HHS

U01 CA244100

NCI NIH HHS

P30 CA076292

NIGMS NIH HHS

K99 GM154063

NIGMS NIH HHS

R35 GM143004

NIH National Institute of General Medical Sciences

R35 GM143004

National Institutes of Health National Cancer Institute

P30-CA076292

National Institutes of Health National Cancer Institute

U01 CA244100-01